Denosumab in postmenopausal women with low bone mineral density.
Schwartzman
Julie
J
Yazici
Yusuf
Y
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015986:Confounding Factors, Epidemiologic; D003627:Data Interpretation, Statistical; D000069448:Denosumab; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D053245:RANK Ligand
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab